Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015, Article ID 616747, 6 pages
http://dx.doi.org/10.1155/2015/616747
Research Article

NLRP3 Inflammasome Polymorphism and Macrovascular Complications in Type 2 Diabetes Patients

1General Hospital Trbovlje, Rudarska cesta 9, SI-1420 Trbovlje, Slovenia
2Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, SI-1000 Ljubljana, Slovenia
3Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, Zaloška Cesta 7, SI-1000 Ljubljana, Slovenia

Received 19 January 2015; Accepted 17 March 2015

Academic Editor: Joseph Fomusi Ndisang

Copyright © 2015 Jasna Klen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Turner, “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group,” The Lancet, vol. 352, no. 9131, pp. 837–853, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. R. R. Holman, S. K. Paul, M. A. Bethel, D. R. Matthews, and H. A. W. Neil, “10-Year follow-up of intensive glucose control in type 2 diabetes,” The New England Journal of Medicine, vol. 359, no. 15, pp. 1577–1589, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Kolb and T. Mandrup-Poulsen, “An immune origin of type 2 diabetes?” Diabetologia, vol. 48, no. 6, pp. 1038–1050, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Pradhan, “Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders,” Nutrition Reviews, vol. 65, no. 12, part 2, pp. S152–S156, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Esser, S. Legrand-Poels, J. Piette, A. J. Scheen, and N. Paquot, “Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes,” Diabetes Research and Clinical Practice, vol. 105, no. 2, pp. 141–150, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. B. C. Cumbie and K. L. Hermayer, “Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications,” Vascular Health and Risk Management, vol. 3, no. 6, pp. 823–832, 2007. View at Google Scholar · View at Scopus
  7. L. Gnudi, “Cellular and molecular mechanisms of diabetic glomerulopathy,” Nephrology Dialysis Transplantation, vol. 27, no. 7, pp. 2642–2649, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Y. Donath, “Targeting inflammation in the treatment of type 2 diabetes: time to start,” Nature Reviews Drug Discovery, vol. 13, no. 6, pp. 465–476, 2014. View at Publisher · View at Google Scholar
  9. E. Benetti, F. Chiazza, N. S. A. Patel, and M. Collino, “The NLRP3 inflammasome as a novel player of the intercellular crosstalk in metabolic disorders,” Mediators of Inflammation, vol. 2013, Article ID 678627, 9 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. D. R. Mason, P. L. Beck, and D. A. Muruve, “Nucleotide-binding oligomerization domain-like receptors and inflammasomes in the pathogenesis of non-microbial inflammation and diseases,” Journal of Innate Immunity, vol. 4, no. 1, pp. 16–30, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Schroder and J. Tschopp, “The inflammasomes,” Cell, vol. 140, no. 6, pp. 821–832, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. J. M. Fernández-Real and J. C. Pickup, “Innate immunity, insulin resistance and type 2 diabetes,” Diabetologia, vol. 55, no. 2, pp. 273–278, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Zheng, D. Zhang, L. Zhang, M. Fu, Y. Zeng, and R. Russell, “Variants of NLRP3 gene are associated with insulin resistance in Chinese Han population with type-2 diabetes,” Gene, vol. 530, no. 1, pp. 151–154, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Chmelar, K.-J. Chung, and T. Chavakis, “The role of innate immune cells in obese adipose tissue inflammation and development of insulin resistance,” Thrombosis and Haemostasis, vol. 109, no. 3, pp. 399–406, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Verma, E. Särndahl, H. Andersson et al., “The Q705K polymorphism in NLRP3 is a gain-of-function alteration leading to excessive interleukin-1β and IL-18 production,” PLoS ONE, vol. 7, no. 4, Article ID e34977, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Sahdo, K. Fransén, B. A. Idosa et al., “Cytokine profile in a cohort of healthy blood donors carrying polymorphisms in genes encoding the NLRP3 inflammasome,” PLoS ONE, vol. 8, no. 10, Article ID e75457, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. G. P. Varghese, K. Fransen, A. Hurtig-Wennlof, T. Bengtsson, J. H. Jansson, and A. Sirsjo, “Q705K variant in NLRP3 gene confers protection against myocardial infarction in female individuals,” Biomedical Reports, vol. 1, no. 6, pp. 879–882, 2013. View at Publisher · View at Google Scholar
  18. A. Dehghan, Q. Yang, A. Peters et al., “Association of novel genetic loci with circulating fibrinogen levels a genome-wide association study in 6 population-based cohorts,” Circulation: Cardiovascular Genetics, vol. 2, no. 2, pp. 125–133, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Dehghan, J. Dupuis, M. Barbalic et al., “Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels,” Circulation, vol. 123, no. 7, pp. 731–738, 2011. View at Google Scholar
  20. J. Klen, V. Dolžan, and A. Janež, “CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients,” European Journal of Clinical Pharmacology, vol. 70, no. 4, pp. 421–428, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Takahashi, “NLRP3 inflammasome as a novel player in myocardial infarction,” International Heart Journal, vol. 55, no. 2, pp. 101–105, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. C. L. Wassel, L. A. Lange, B. J. Keating et al., “Association of genomic loci from a cardiovascular gene SNP array with fibrinogen levels in European Americans and African-Americans from six cohort studies: the Candidate Gene Association Resource (CARe),” Blood, vol. 117, no. 1, pp. 268–275, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Kawaguchi, M. Takahashi, T. Hata et al., “Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury,” Circulation, vol. 123, no. 6, pp. 594–604, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Li, S. Xu, B. Jiang, R. A. Cohen, and M. Zang, “Activation of sterol regulatory element binding protein and NLRP3 inflammasome in atherosclerotic lesion development in diabetic pigs,” PLoS ONE, vol. 8, no. 6, Article ID e67532, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. C. M. Turner, N. Arulkumaran, M. Singer, R. J. Unwin, and F. W. Tam, “Is the inflammasome a potential therapeutic target in renal disease?” BMC Nephrology, vol. 15, no. 1, article 21, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Fujita, N. Ogihara, Y. Kamura et al., “Interleukin-18 contributes more closely to the progression of diabetic nephropathy than other diabetic complications,” Acta Diabetologica, vol. 49, no. 2, pp. 111–117, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Carlström, A.-K. Ekman, S. Petersson, P. Söderkvist, and C. Enerbäck, “Genetic support for the role of the NLRP3 inflammasome in psoriasis susceptibility,” Experimental Dermatology, vol. 21, no. 12, pp. 932–937, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. R. J. Mathews, J. I. Robinson, M. Battellino et al., “Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment,” Annals of the Rheumatic Diseases, vol. 73, no. 6, pp. 1202–1210, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Ben Hamad, F. Cornelis, S. Marzouk et al., “Association study of CARD8 (p.C10X) and NLRP3 (p.Q705K) variants with rheumatoid arthritis in French and Tunisian populations,” International Journal of Immunogenetics, vol. 39, no. 2, pp. 131–136, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Yang, S. Huang, and B. Chiang, “Association of NLRP3 and CARD8 genetic polymorphisms with juvenile idiopathic arthritis in a Taiwanese population,” Scandinavian Journal of Rheumatology, vol. 43, no. 2, pp. 146–152, 2014. View at Publisher · View at Google Scholar
  31. Y. Bai, S. Nie, G. Jiang et al., “Regulation of CARD8 expression by ANRIL and association of CARD8 single nucleotide polymorphism rs2043211 (p.C10X) with ischemic stroke,” Stroke, vol. 45, no. 2, pp. 383–388, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Vidan-Jeras, B. Jurca, V. Dolžan, M. Jeras, K. Breskvar, and M. Bohinjec, “Slovenian caucasian normal,” in HLA 1998, P. I. Terasaki and D. W. Gjerston, Eds., pp. 180–181, American Society for Histocompatibility and Immunogenetics, Lenexa, Kan, USA, 1998. View at Google Scholar
  33. G. Parati, G. Bilo, and J. E. Ochoa, “Benefits of tight blood pressure control in diabetic patients with hypertension: importance of early and sustained implementation of effective treatment strategies,” Diabetes Care, vol. 34, supplement 2, pp. S297–S303, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Scarpioni, M. Ricardi, V. Albertazzi, and L. Melfa, “Treatment of dyslipidemia in chronic kidney disease: effectiveness and safety of statins,” World Journal of Nephrology, vol. 1, no. 6, pp. 184–194, 2012. View at Google Scholar
  35. A. González-Chávez, S. Elizondo-Argueta, G. Gutiérrez-Reyes, and J. I. León-Pedroza, “Pathophysiological implications between chronic inflammation and the development of diabetes and obesity,” Cirugia y Cirujanos, vol. 79, no. 2, pp. 209–216, 2011. View at Google Scholar · View at Scopus
  36. K. M. Sumpter, S. Adhikari, E. K. Grishman, and P. C. White, “Preliminary studies related to anti-interleukin-1beta therapy in children with newly diagnosed type 1 diabetes,” Pediatric Diabetes, vol. 12, no. 7, pp. 656–667, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Alexandraki, C. Piperi, C. Kalofoutis, J. Singh, A. Alaveras, and A. Kalofoutis, “Inflammatory process in type 2 diabetes: the role of cytokines,” Annals of the New York Academy of Sciences, vol. 1084, pp. 89–117, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. B. S. Nikolajczyk, M. Jagannathan-Bogdan, H. Shin, and R. Gyurko, “State of the union between metabolism and the immune system in type 2 diabetes,” Genes and Immunity, vol. 12, no. 4, pp. 239–250, 2011. View at Publisher · View at Google Scholar · View at Scopus